Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00193193 | Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma | PHASE2 | COMPLETED | 100 | — | — | Aug 1, 2000 | Feb 1, 2007 | Aug 4, 2010 | - | — |
| Name | Type | Description |
|---|---|---|
| Paclitaxel | DRUG | - |
| Estramustine | DRUG | - |
| Carboplatin | DRUG | - |
Inclusion Criteria: * Adenocarcinoma of the prostate not curable with local treatment * Disease progression while receiving hormonal therapy * Measurable or evaluable disease * Previous treatment with a maximum of one prior chemotherapy regimen * ECOG performance status 0, 1, or 2. * Adequate bone ...